Scientific Reviews
Product Guides
Blogs
Topics
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!2025-02-06
156 Results for "
lateral
" in MedChemExpress (MCE) Product Catalog:
Products (156)
156 Results for "lateral" in MCE Product Catalog:
Target:
Research Areas:
GDC-0134 (RG6000) is a modulator targeting dual leucine zipper kinase (DLK) that can cross the blood-brain barrier. By inhibiting the kinase activity of DLK, GDC-0134 blocks the activation of the downstream JNK signaling pathway, suppresses DLK-dependent retrograde signal transduction of axon-to-soma degeneration, and exerts neuroprotective activity. GDC-0134 reduces TDP-43 protein aggregation and decreases the degree of neuromuscular junction denervation in motor neurons. GDC-0134 can be used in the research of amyotrophic lateral sclerosis (ALS), Alzheimer's disease and other DLK-related neurodegenerative diseases .
Cat. No.: HY-187892
CAS No.: 3060541-19-4
Synonyms: ATH-1105
Target:
Research Areas:
Brelgometon (ATH-1105) is an orally active HGF/MET positive modulator . Brelgometon activates downstream ERK and AKT cascades. Brelgometon reduces pro-inflammatory cytokine levels and extranuclear TDP-43 aggregation; it also upregulates EAAT2 expression and improves mitochondrial function. Brelgometon protects neurons from excitotoxicity, inflammation, oxidative stress and mitochondrial dysfunction; it also maintains neurite length, neuromuscular junction integrity and sciatic nerve function. Brelgometon alleviates motor function deterioration, maintains body weight and prolongs survival in ALS transgenic mice. Brelgometon is applicable to research related to amyotrophic lateral sclerosis .
Cat. No.: HY-P11124
CAS No.: 1611488-66-4
Research Areas:
Cat. No.: HY-W141374
CAS No.: 108883-90-5
Target:
Research Areas:
CB096 is an r(G4C2) exp RNA binder with EC50 values of 19 μM, 20 μM and 33 μM. CB096 selectively interacts with the 5′CGG/3′GGC 1×1 GG internal loop motif of folded r(G4C2) exp RNA, alters motif dynamics and closed base pairs, and rescues disease-related pathways. CB096 can be used for research on inherited amyotrophic lateral sclerosis/frontotemporal dementia (c9ALS/FTD) .
Cat. No.: HY-W611371
CAS No.: 61694-81-3
Target:
Research Areas:
FP802 is an orally active potent TwinF interface inhibitor that disrupts and detoxifies the NMDAR/TRPM4 death complex. FP802 exerts powerful neuroprotective effects in the 5xFAD mouse model of Alzheimer’s disease (AD) by preventing cognitive decline, preserving neuronal structural integrity, reducing amyloid-β plaque formation, and mitigating mitochondrial pathology . FP802 stops loss of motor neurons, reduces serum neurofilament light chain (NfL) levels, improves motor performance, and extends life in a mouse model of amyotrophic lateral sclerosis (ALS). FP802 can be used for AD and ALS research .
Cat. No.: HY-P702771
Purity: ≥ 90%, as determined by reducing SDS-PAGE.
Synonyms: RPLP0; LP0; Ribosomal Protein lateral Stalk Subunit P0; P0; Large Ribosomal Subunit Protein UL10; Neutral Ribosomal Phosphoprotein P0; 60S Acidic Ribosomal Protein P0; Ribosomal Protein, Large, P0; PRLP0; 60S Ribosomal Protein L10E; L10E; Acidic Ribosomal
Species:
Mouse
Source:
E. coli
Cat. No.: HY-168007
Target:
Research Areas:
NSC804515 is an inhibitor of wild-type and R155H mutant p97/VCP ATPase, with an IC50 of about 15 nM for both targets. NSC804515 acts as an antiproliferative agent, disrupts the function of the ubiquitin-proteasome system, induces UbG76V-GFP accumulation, and shows reduced inhibitory potency against p97 variants carrying P510S, K512N, N616F and F618S mutations. NSC804515 can be used in research related to cancer, inclusion body myopathy with early-onset Paget's disease and frontotemporal dementia, as well as familial amyotrophic lateral sclerosis .
Cat. No.: HY-172902
CAS No.: 3105281-39-5
Target:
Research Areas:
RNA binder 1 (Compound 4b) is a blood-brain permeable RNA binder. RNA binder 1 can selectively bind to the G-quadruplex structure of the G4C2 repeat sequence RNA of the C9orf72 gene. RNA binder 1 significantly reduces the levels of toxic polypeptides poly(GA) and poly(GP) produced by the G4C2 repeat sequence in amyotrophic lateral sclerosis (ALS) patient-derived cells. RNA binder 1 has no significant effect on the antisense polypeptide poly(PR), showing selectivity for sense RNA. RNA binder 1 can be used in the study of ALS and frontotemporal dementia (FTD) .
Cat. No.: HY-184593
Target:
Research Areas:
UM-232 is a highly selective covalent STING antagonist with an EC50 of 6.20 μM in STING R232-expressing THP-1 cells. UM-232 covalently targets C292 and C309 cysteines of STING, blocks STING oligomerization and inhibits downstream TBK1/IRF3 activation and proinflammatory cytokine transcription. UM-232 has low off-target reactivity and good hepatic stability, serving as a chemical probe for STING-driven autoimmune and inflammatory diseases including Aicardi-Goutières syndrome (AGS), Systemic Lupus Erythematosus (SLE) and Amyotrophic Lateral Sclerosis (ALS) .
Cat. No.: HY-W611371A
CAS No.: 2490401-57-3
Target:
Research Areas:
FP802 dihydrochloride is an orally active potent TwinF interface inhibitor that disrupts and detoxifies the NMDAR/TRPM4 death complex. FP802 dihydrochloride exerts powerful neuroprotective effects in the 5xFAD mouse model of Alzheimer’s disease (AD) by preventing cognitive decline, preserving neuronal structural integrity, reducing amyloid-β plaque formation, and mitigating mitochondrial pathology . FP802 dihydrochloride stops loss of motor neurons, reduces serum neurofilament light chain (NfL) levels, improves motor performance, and extends life in a mouse model of amyotrophic lateral sclerosis (ALS) . FP802 dihydrochloride can be used for AD and ALS research .
Cat. No.: HY-W010178
CAS No.: 54947-74-9
Target:
Cat. No.: HY-P701362
Purity: ≥ 90%, as determined by reducing SDS-PAGE.
Synonyms: CDK15; Serine/Threonine-Protein Kinase PFTAIRE-2; Prev. ALS2CR7; Cell Division Protein Kinase 15; Prev. PFTK2; Cyclin-Dependent Kinase 15; PFTAIRE2; PFTAIRE Protein Kinase 2; Amyotrophic lateral Sclerosis 2 Chromosomal Region Candidate Gene 7 Protein; Ser
Species:
Human
Source:
Sf9 insect cells
Cat. No.: HY-P702695
Purity: ≥ 90%, as determined by reducing SDS-PAGE.
Synonyms: CDK15; Serine/Threonine-Protein Kinase PFTAIRE-2; Prev. ALS2CR7; Cell Division Protein Kinase 15; Prev. PFTK2; Cyclin-Dependent Kinase 15; PFTAIRE2; PFTAIRE Protein Kinase 2; Amyotrophic lateral Sclerosis 2 Chromosomal Region Candidate Gene 7 Protein; Ser
Species:
Human
Source:
Sf9 insect cells
Cat. No.: HY-113286R
CAS No.: 463-00-3
Research Areas:
QC-01-175 is a Tau PROTAC degrader, with Kd values of 1.2 μM, 1.7 μM and 2.5 μM for wild-type, A152T mutant and P301L mutant tau-441 proteins, respectively. QC-01-175 binds to both Tau and CRBN, triggering ubiquitination and proteasomal degradation of Tau. QC-01-175 preferentially targets disease-associated Tau proteins in frontotemporal dementia. QC-01-175 inhibits MAO activity, with an IC50 of 8.56 μM. QC-01-175 suppresses the elevation of ROS levels. QC-01-175 can be used in studies related to frontotemporal dementia and amyotrophic lateral sclerosis .
Target:
Research Areas:
rTRD01 is an orally active, specific TDP-43 binder that targets the RRM1 and RRM2 domains of TDP-43. rTRD01 partially disrupts the interaction between TDP-43 and c9orf72 repeat RNA, but does not affect the binding of TDP-43 to canonical binding sequences. rTRD01 exhibits significant neuroprotective effects in zebrafish models, improves motor function and protects against paraquat (a widely used herbicide)-induced neurodegeneration, with no teratogenicity at high concentrations. rTRD01 is not a general antioxidant and cannot counteract Rotenone (HY-B1756)-induced neuronal death. rTRD01 can be used to study amyotrophic lateral sclerosis and other TDP-43 proteinopathies .
Cat. No.: HY-186072
CAS No.: 2771019-10-2
Research Areas:
Neurological Disease Metabolic Disease Inflammation/Immunology
NT-0527 is a selective, orally active, and brain-permeable NLRP3 inflammasome inhibitor. NT-0527 can specifically block the formation of the NLRP3 inflammasome, resulting in the reduction in the maturation and release of IL-1β, exhibit inhibition on CYP2C19. NT-0527 displays anti-inflammatory activity in the mouse LPS (HY-D1056) /ATP (HY-B2176)-induced peritonitis model. NT-0527 can be used for the research of neuroinflammatory disorders (Parkinson's disease, Alzheimer's disease, amyotrophic lateral sclerosis) and peripheral inflammatory disorders (type II diabetes, atherosclerosis, gout, etc.) associated with NLRP3 inflammasome .
Cat. No.: HY-186073
CAS No.: 300399-36-4
Target:
Research Areas:
HDAC1 activator-1 is a specific HDAC1 activator with orally activity, exerting no significant effects on other HDAC family members. HDAC1 activator-1 exhibits neuroprotective activity, ameliorates cognitive and motor function deficits by reducing neuronal loss and gliosis. HDAC1 activator-1 specifically activates HDAC1 in SH-SY5Y cells and exerts regulatory effects on aberrant cell cycle and DNA damage. HDAC1 activator-1 can be used for the research of TDP-43 proteinopat1-related neurodegenerative diseases including Amyotrophic Lateral Sclerosis (ALS) and cerebral ischemia-related neurological injury .
Cat. No.: HY-132580S
Synonyms: BIIB067-d27; ISIS-SOD1Rx-d27; ISIS 333611-d27
Target:
Research Areas:
NCI-65828 (N-65828) sodium is a cell-permeable small molecule inhibitor. NCI-65828 inhibits the ribonuclease activity of human angiogenin and zebrafish Rnasel-1/3, as well as the activity of Mycobacterium tuberculosis AccD5 and its holoenzyme complex. NCI-65828 induces neuronal developmental defects, impairs vascular development, inhibits neurite outgrowth, and reduces protein synthesis in stem cells and neural progenitor cells, but shows no significant growth inhibitory effect on various human tumor cell lines. NCI-65828 is primarily used to study the role of angiogenin-like ribonucleases in neural and vascular development, to establish effect models of ALS-related angiogenin mutants, and in research related to amyotrophic lateral sclerosis, frontotemporal dementia, and tuberculosis .
-
-
Protocols
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!A suitable model is crucial in drug screening experiments. Organs can mimic the three-dimensional functional structure of internal organs, have similar spatial organization to corresponding organs, maintain some key characteristics, and reproduce some physiological functions. They are widely used for modeling and personalized drug screening physiological functions.2025-02-06
